How to buy Cabaletta Bio (CABA) stock

Cabaletta Bio, Inc is a biotechnology business based in the US. Cabaletta Bio shares (CABA) are listed on the NASDAQ and all prices are listed in US Dollars. Cabaletta Bio employs 35 staff and has a market cap (total outstanding shares value) of 0.00.

Cabaletta Bio stock price (NASDAQ: CABA)

Use our graph to track the performance of CABA stocks over time.

Cabaletta Bio shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$11.34
52-week range	$7.05 - $16.38
50-day moving average	$8.15
200-day moving average	$10.70
Wall St. target price	$22.60
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.94

Buy Cabaletta Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Cabaletta Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Cabaletta Bio, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cabaletta Bio price performance over time

Historical closes compared with the close of $11.34 from 2021-05-28

1 week (2021-07-15)	N/A
1 month (2021-06-25)	51.60%
3 months (2021-04-26)	2.53%
6 months (2021-01-22)	N/A

1 year (2020-07-22)	N/A
2 years (2019-07-22)	N/A
3 years (2018-07-22)	N/A
5 years (2016-07-22)	N/A

Cabaletta Bio financials

Gross profit TTM	$0
Return on assets TTM	-18.4%
Return on equity TTM	-30.26%
Profit margin	0%
Book value	$4.26
Market capitalisation	$204.9 million

TTM: trailing 12 months

Shorting Cabaletta Bio shares

There are currently 1.4 million Cabaletta Bio shares held short by investors – that's known as Cabaletta Bio's "short interest". This figure is 12.1% down from 1.6 million last month.

There are a few different ways that this level of interest in shorting Cabaletta Bio shares can be evaluated.

Cabaletta Bio's "short interest ratio" (SIR)

Cabaletta Bio's "short interest ratio" (SIR) is the quantity of Cabaletta Bio shares currently shorted divided by the average quantity of Cabaletta Bio shares traded daily (recently around 223044.28104575). Cabaletta Bio's SIR currently stands at 6.12. In other words for every 100,000 Cabaletta Bio shares traded daily on the market, roughly 6120 shares are currently held short.

However Cabaletta Bio's short interest can also be evaluated against the total number of Cabaletta Bio shares, or, against the total number of tradable Cabaletta Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cabaletta Bio's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Cabaletta Bio shares in existence, roughly 50 shares are currently held short) or 0.1297% of the tradable shares (for every 100,000 tradable Cabaletta Bio shares, roughly 130 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Cabaletta Bio.

Find out more about how you can short Cabaletta Bio stock.

Cabaletta Bio share dividends

We're not expecting Cabaletta Bio to pay a dividend over the next 12 months.

Cabaletta Bio overview

Cabaletta Bio, Inc. , a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California.

Frequently asked questions

What percentage of Cabaletta Bio is owned by insiders or institutions?
Currently 4.907% of Cabaletta Bio shares are held by insiders and 65.739% by institutions. How many people work for Cabaletta Bio?
Latest data suggests 35 work at Cabaletta Bio. When does the fiscal year end for Cabaletta Bio?
Cabaletta Bio's fiscal year ends in December. Where is Cabaletta Bio based?
Cabaletta Bio's address is: 2929 Arch Street, Philadelphia, PA, United States, 19104 What is Cabaletta Bio's ISIN number?
Cabaletta Bio's international securities identification number is: US12674W1099 What is Cabaletta Bio's CUSIP number?
Cabaletta Bio's Committee on Uniform Securities Identification Procedures number is: 12674W109